Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Clinical trials

Increasing diversity and inclusion in nephrology clinical trials

Nature Reviews Nephrology volume 19, pages 627–628 (2023)Cite this article

Subjects

Racial and ethnic minoritized populations are underrepresented in clinical trials in nephrology, but overrepresented in adverse kidney disease outcomes. Targeted enrolment, revision of problematic policies, inclusion of minoritized populations in trial planning, and language-, race- and ethnicity-concordant investigative teams can improve representation in clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Strategies to increase diverse clinical trial participation.

References

  1. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: ethical principles and guidelines for protection of human subjects of biomedical and behavioral research. Fed. Regist. 44, 23192–23197 (1979).

    Google Scholar 

  2. Soomro, Q. H. et al. Representation of racial and ethnic minorities in nephrology clinical trials: a systematic review and meta-analysis. J. Am. Soc. Nephrol. 34, 1167–1177 (2023).

    Article  PubMed  Google Scholar 

  3. Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials guidance for industry. fda.gov, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations (2022).

  4. Turner, B. E., Steinberg, J. R., Weeks, B. T., Rodriguez, F. & Cullen, M. R. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg. Health Am. 11, 100252 (2022).

    PubMed  PubMed Central  Google Scholar 

  5. Kaiser Family Foundation. COVID-19 racial disparities in testing, infection, hospitalization, and death: analysis of Epic patient data. KFF.org, https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-racial-disparities-testing-infection-hospitalization-death-analysis-epic-patient-data/ (2020).

  6. National Kidney Foundation Research Roundtable Work Group on behalf of the National Kidney Foundation. Research priorities for kidney-related research—an agenda to advance kidney care: a position statement from the National Kidney Foundation. Am. J. Kidney Dis. 79, 141–152 (2022).

    Article  Google Scholar 

  7. United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States (NIDDK, 2022).

  8. Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 96, 1048–1050 (2019).

    Article  PubMed  Google Scholar 

  9. Sanossian, N. et al. A dedicated Spanish language line increases enrollment of Hispanics into prehospital clinical research. Stroke 48, 1389–1391 (2017).

    Article  PubMed  Google Scholar 

  10. Ford, J. G. et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112, 228–242 (2008).

    Article  PubMed  Google Scholar 

  11. George, S., Duran, N. & Norris, K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am. J. Public Health 104, e16–e31 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Office of Healthcare Equity, University of Washington Justice, Equity, Diversity, and Inclusion Center for Transformational Research, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA

    Bessie A. Young

  2. Kidney and Hypertension Unit, Joslin Diabetes Center, Harvard University, Boston, MA, USA

    Sylvia E. Rosas

Authors
  1. Bessie A. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sylvia E. Rosas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sylvia E. Rosas.

Ethics declarations

Competing interests

S.E.R. participated in at least one advisory board for AstraZeneca, Bayer and Traverse, and the Joslin Diabetes Center receives research support from AstraZeneca and Bayer. B.A.Y. declares no competing interests.

Additional information

Related links

ICJME recommendations: https://www.icmje.org/icmje-recommendations.pdf

NMRI: https://www.niddk.nih.gov/research-funding/research-programs/diversity-programs/network-minority-health-research-investigators-nmri

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Young, B.A., Rosas, S.E. Increasing diversity and inclusion in nephrology clinical trials. Nat Rev Nephrol 19, 627–628 (2023). https://doi.org/10.1038/s41581-023-00756-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-023-00756-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing